drugset / Trial / NCT02993991
Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity
Phase 1
Withdrawn
University Health Network, Toronto
AstraZeneca · collabMirati Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 Window of Opportunity study to evaluate the pharmacodynamic and immune effects of pre-operative therapy with Mocetinostat and Durvalumab on patients with squamous cell carcinoma of the oral cavity.
Timeline
- Start
- 2017-10-10
- Primary completion
- 2017-12-21
- Completion
- 2017-12-21
Outcome
Outcome not reported
Stopped: “The study has been terminated due to a change in internal prioritization and not due to any safety concerns.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | — |
| Subject | Mocetinostat | Small molecule | 70 mg | Oral |
| Subject | Mocetinostat | Small molecule | 90 mg | Oral |